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  Background  Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International 
Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant 
chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel. 
  Methods  Patients with lymph node – positive breast cancer (n = 2887) were randomly assigned to one of four 
treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m 2 , followed by three cycles of 
cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxo-
rubicin at 60 mg/m 2 plus cyclophosphamide at 600 mg/m 2 , followed by three cycles of CMF); 3) sequential 
docetaxel (three cycles of doxorubicin at 75 mg/m 2 , followed by three cycles of docetaxel at 100 mg/m 2 , 
followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m 2 plus 
docetaxel at 75 mg/m 2 , followed by three cycles of CMF). The primary comparison evaluated the efficacy 
of including docetaxel regardless of schedule and was planned after 1215 disease-free survival (DFS) 
events (ie, relapse, second primary cancer, or death from any cause). Docetaxel and control treatment 
groups were compared by log-rank tests, and hazard ratios (HR) of DFS events were calculated by Cox 
modeling. All statistical tests were two-sided. 
  Results  Due to a lower-than-anticipated rate of relapse, this analysis was performed after 5 years with 732 events. 
Patients in control arms had a 5-year DFS of 73% (95% confidence interval [CI] = 70% to 75%). Docetaxel 
treatment resulted in an improvement in DFS of borderline statistical significance compared with control 
treatment (HR = 0.86, 95% CI = 0.74 to 1.00;  P = .05). However, DFS in the sequential docetaxel arm was 
better than that in the concurrent docetaxel arm (HR = 0.83, 95% CI = 0.69 to 1.00) and in the sequential 
control arm (HR = 0.79, 95% CI = 0.64 to 0.98). 
  Conclusions  Incorporating docetaxel into anthracycline-based therapy resulted in an improvement in DFS that was of 
borderline statistical significance. However, important differences may be related to doxorubicin and 
docetaxel scheduling, with sequential but not concurrent administration, appearing to produce better DFS 
than anthracycline-based chemotherapy. 
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 Thirty years ago, Bonadonna et al. ( 1 ) reported the initial results 
of the Milan randomized trial testing 12 months of adjuvant che-
motherapy with cyclophosphamide, methotrexate, and 5-ﬂ uoro-
uracil (CMF) in patients with lymph node – positive breast cancer. 
Patients who received CMF had a statistically signiﬁ cantly lower 
risk of relapse than those who did not receive chemotherapy, with 
relapse-free survival rates of 60% vs 45%, respectively, at 5 years 
( 2 ). Subsequently, the effect on relapse rates of 12 months or 
6 months of CMF were compared in a randomized trial and were 
not found to be statistically signiﬁ cantly different ( 3 ). In 1990, the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-15 randomized trial reported no statistically signiﬁ cant dif-
ference in disease-free survival (DFS) with a shorter course 
(3 months) of four cycles of doxorubicin plus cyclophosphamide 
compared with 6 months of CMF ( 4 ). However, improvements in 
adjuvant breast cancer therapy were needed, particularly for 
patients with four or more positive lymph nodes who had a 5-year 
relapse-free survival of only 41% in the initial CMF trial. 
 In 1991, Buzzoni et al. ( 5 ) reported that outcomes among 
women treated with a strategy of sequential adjuvant chemother-
apy with four cycles of doxorubicin at 75 mg/m 2 , followed by 
6 months of intravenous CMF, were superior to those among 
women treated with an alternating drug schedule. That trial, 
which was conducted in breast cancer patients with four or more 
positive lymph nodes, reported a 5-year DFS of 61% for the 
sequential arm. Consequently, in 1997 when we planned the ﬁ rst 
randomized adjuvant chemotherapy trial conducted by the Breast 
International Group (BIG 02-98 trial), crossover anthracycline-
CMF chemotherapy was considered to be an appropriate control 
treatment for patients with lymph node – positive breast cancer. For 
the CMF component, we chose classical CMF, which includes oral 
cyclophosphamide, rather than intravenous CMF, because of its 
superior efﬁ cacy in patients with advanced disease ( 6 ). The dura-
tion of CMF treatment was also shortened, so that the total dura-
tion of control arm chemotherapy was 6 months. 
 Docetaxel (Taxotere) is a taxane with activity in anthracycline-
resistant breast cancer ( 7 , 8 ). A phase III trial in patients with meta-
static breast cancer ( 9 ) had reported a statistically signiﬁ cantly 
higher response rate to treatment with docetaxel at 100 mg/m 2 
than to treatment with doxorubicin at 75 mg/m 2 . It was therefore 
a priority to test docetaxel in the adjuvant setting. The BIG 02-98 
trial was designed to test whether incorporating docetaxel into 
anthracycline-based adjuvant chemotherapy could improve results 
compared with optimal anthracycline-based adjuvant chemother-
apy regimens that were administered for approximately the same 
duration. This trial was also designed to assess whether docetaxel 
should be administered sequentially after doxorubicin or concur-
rently with doxorubicin; concurrent administration required that 
the dose of both drugs be reduced ( 10 ). A pilot study ( 11 ) tested 
the feasibility of the experimental docetaxel arms before this phase 
III trial. We report the results of the BIG 02-98 trial after a median 
follow-up of 62.5 months. 
 Patients and Methods 
 Patient Eligibility Criteria 
 Eligible patients were aged 18 – 70 years with operable, clinical stage 
T1 – 3 invasive breast adenocarcinoma. They were required to have 
resected tumors with clear margins after either mastectomy or 
breast-conserving surgery and at least one positive axillary lymph 
node among a minimum of eight dissected lymph nodes. Registration 
was required within 60 days of surgery. The determination of estro-
gen receptor and progesterone receptor status was mandatory. 
Staging that included a chest x-ray or computerized tomography 
scan, a bone scan, and an abdominal ultrasound or computerized 
tomography scan was required. A normal left ventricular ejection 
fraction and adequate hematologic, liver, and renal function were 
required. Exclusion criteria included supraclavicular lymph node 
involvement, distant metastases, previous cancers, neuropathy of 
grade 2 or higher, or serious medical conditions. Written or wit-
nessed informed consent was required. The protocol was approved 
by Institutional Ethics Committees. 
 Protocol Therapy 
 Treatment allocation was done centrally by use of a minimization 
procedure ( 12 ) with stratification for center, number of positive 
axillary lymph nodes, and age. Patients (n = 2887) were randomly 
assigned at a ratio of 1  :  1  :  2  :  2 to one of the following four adjuvant 
chemotherapy regimen arms ( Fig. 1 ): 1) sequential control arm 
(four cycles of intravenous doxorubicin at 75 mg/m 2 every 3 weeks, 
followed by three cycles of CMF); 2) concurrent control arm (four 
cycles of intravenous doxorubicin at 60 mg/m 2 plus intravenous 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Docetaxel is more effective than doxorubicin for patients with 
advanced breast cancer. 
 Study design 
 Phase III randomized adjuvant therapy trial of sequential control 
(doxorubicin followed by cyclophosphamide, methotrexate, and 
5-fluorouracil [CMF]), concurrent control (doxorubicin plus cyclo-
phosphamide followed by CMF), sequential docetaxel (doxorubicin 
followed by docetaxel followed by CMF), and concurrent docetaxel 
(doxorubicin plus docetaxel followed by CMF). The primary end 
point was the comparison of disease-free survival (DFS) events (ie, 
relapse, second primary cancer, or death from any cause). 
 Contribution 
 Incorporating docetaxel into anthracycline-based chemotherapy 
resulted in an improvement of DFS that was of borderline statisti-
cal significance. Important differences may be related to docetaxel 
and doxorubicin scheduling, with sequential administration appear-
ing to produce better DFS than concurrent administration. 
 Implications 
 Scheduling of doxorubicin and docetaxel for the treatment of 
breast cancer appears to warrant further study. 
 Limitations 
 After a median follow-up of at least 5 years, less than two-thirds of 
the number of DFS events originally planned had occurred at the 
time of this analysis. Consequently, the study had reduced power. 
The better sequential docetaxel result could have arisen by chance. 
Differences in DFS may not translate into differences in overall 
survival. 
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cyclophosphamide at 600 mg/m 2 every 3 weeks, followed by three 
cycles of CMF); 3) sequential docetaxel arm (three cycles of intra-
venous doxorubicin at 75 mg/m 2 every 3 weeks, followed by three 
cycles of intravenous docetaxel at 100 mg/m 2 every 3 weeks, fol-
lowed by three cycles of CMF); 4) concurrent docetaxel arm (four 
cycles of intravenous doxorubicin at 50 mg/m 2 plus intravenous 
docetaxel at 75 mg/m 2 every 3 weeks with docetaxel commencing 
1 hour after doxorubicin, followed by three cycles of CMF). 
Patients in all arms received three cycles of CMF that were given 
every 4 weeks as oral cyclophosphamide at 100 mg/m 2 on days 
1 – 14 and intravenous methotrexate at 40 mg/m 2 plus intravenous 
5-fluorouracil at 600 mg/m 2 on days 1 and 8. During the CMF 
cycles, if oral cyclophosphamide could not be tolerated, a switch to 
intravenous cyclophosphamide at 600 mg/m 2 on days 1 and 8 was 
allowed. The planned cumulative doxorubicin dose was higher in 
the control arms (sequential = 300 mg/m 2 or concurrent = 240 mg/
m 2 ) than in the docetaxel arms (sequential = 225 mg/m 2 or concur-
rent = 200 mg/m 2 ). Both docetaxel arms had the same planned 
cumulative dose of docetaxel (ie, 300 mg/m 2 ). The duration of each 
treatment regimen was 24 weeks, except for the sequential docetaxel 
regimen that was 30 weeks. 
 Docetaxel was infused over a 1-hour period with routine steroid 
premedication over a 3-day period starting the day before treat-
ment. Patients received prophylactic oral ciproﬂ oxacin at 500 mg 
twice a day on days 6 – 12 of each cycle of concurrent doxorubicin 
plus docetaxel because of the anticipated risk of febrile neutrope-
nia. No primary prophylaxis with granulocyte colony-stimulating 
factor was permitted; however, granulocyte colony-stimulating 
factor was recommended after subsequent doses of doxorubicin 
and/or docetaxel if previous febrile neutropenia, grade 3 – 4 infec-
tion, or a treatment delay of more than 7 days occurred because of 
neutropenia. If these problems recurred despite treatment with 
granulocyte colony-stimulating factor, then dose reduction was 
required. Treatment cycles were commenced if neutrophil counts 
were at least 1.5 × 10 9 neutrophils per liter and platelet counts 
were at least 100 × 10 9 platelets per liter. CMF was administered 
on days 8 – 14 if on day 8 the neutrophil count was at least 1.0 × 10 9 
neutrophils per liter and the platelet count was at least 100 × 10 9 
platelets per liter. A dose reduction was required for the speciﬁ c 
drug or drug combinations if severe (grade 3 or higher) nonhema-
tologic toxicity developed (eg, the combination of doxorubicin 
at 50 mg/m 2 plus docetaxel at 75 mg/m 2 was reduced to doxorubi-
cin at 40 mg/m 2 plus docetaxel at 60 mg/m 2 or single-agent 
docetaxel at 100 mg/m 2 was reduced to 75 mg/m 2 ). Actual body 
weight was used to calculate body surface area, and, after an 
amendment to the study protocol, the maximum body surface area 
was limited to 2.0 m 2 . Clinical, hematologic, and biochemical 
assessments were required before each cycle, including assessment 
of toxic effects according to the Common Toxicity Criteria, 
Version 1, of the National Cancer Institute. 
 After chemotherapy treatment, tamoxifen at 20 mg orally per 
day for 5 years was commenced for patients with hormone recep-
tor (estrogen receptor and/or progesterone receptor) – positive 
tumors. Cooperative groups or institutions were allowed to declare 
a threshold for designating a tumor hormone receptor – positive 
(eg,  ≥ 1% or  ≥ 10% of cells positive by immunohistochemistry) for 
initiation of adjuvant hormonal therapy. A protocol amendment 
in 2004 allowed for the use of sequential aromatase inhibitors in 
postmenopausal women and the addition of ovarian suppression in 
premenopausal women. This trial was conducted before the use of 
adjuvant trastuzumab therapy. Radiation therapy was mandatory 
after breast-conserving surgery and administered after mastectomy 
according to institutional guidelines. The protocol recommended 
that radiation therapy begin 4 – 6 weeks after day 1 of the ﬁ nal cycle 
of CMF. Protocol-scheduled follow-up of 10 years was planned. 
 Statistical Considerations 
 The study was a phase III prospective, multicenter, nonblinded, 
randomized trial with patients stratified after breast cancer surgery 
according to center, number of positive lymph nodes (1 – 3 vs  ≥ 4), 
and age (<50 vs  ≥ 50 years). The BIG 02-98 trial design incorpo-
rated two control arms (ie, sequential and concurrent control arms) 
and two experimental arms (ie, sequential and concurrent docetaxel 
arms), with twice as many patients randomly assigned to experi-
mental treatments as to control treatments. The primary compari-
son evaluated the role of docetaxel regardless of its schedule of 
administration: (sequential docetaxel plus concurrent docetaxel 
treatments) vs (sequential control plus concurrent control treat-
ments). The secondary objectives were to compare the sequential 
docetaxel arm with the sequential control arm, the concurrent 
docetaxel arm with the concurrent control arm, and the sequential 
docetaxel arm with the concurrent docetaxel arm. Additional sec-
ondary objectives of the trial were to compare the overall survival 
and toxicity among the treatment arms and to evaluate pathologic 
and molecular markers. 
 All randomly assigned patients were included in an intention-
to-treat analysis and were evaluated for both disease-free and 
overall survival. DFS was calculated from the date of randomiza-
tion to the ﬁ rst date of a local, regional, or distant relapse; of the 
diagnosis of a second primary cancer, including contralateral 
  
 Fig. 1 .  Treatment schema for the Breast International Group 02-98 Trial. 
Patients with resected lymph node – positive breast cancer were included 
and stratiﬁ ed according to center, number of positive lymph nodes (1 – 3 
or  ≥ 4 lymph nodes), and age (<50 or  ≥ 50 years). The randomly allocated 
treatments are shown to the right above  boxes , each of which repre-
sents one cycle and are ﬁ lled to illustrate each treatment. A 75 = doxo-
rubicin at 75 mg/m 2 ; CMF = cyclophosphamide, methotrexate, and 
5-ﬂ uorouracil; AC 60/600 = doxorubicin at 60 mg/m 2 plus cyclophospha-
mide at 600 mg/m 2 ; T 100 = docetaxel at 100 mg/m 2 ; AT 50/75 = doxoru-
bicin at 50 mg/m 2 plus docetaxel at 75 mg/m 2 . 
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invasive breast cancer; or of death from any cause. The Kaplan-
Meier product-limit method was used to estimate DFS and overall 
survival, and the stratiﬁ ed log-rank test was used to compare DFS 
and overall survival among treatment groups. Hazard ratios (HR) 
were calculated with a Cox model. All statistical tests were two-
sided. Heterogeneity among centers was not assessed. 
 The primary efﬁ cacy analysis was the comparison of DFS 
between the docetaxel treatment group and the control treat-
ment group. The original planned sample size was 2200 patients, 
and control patients were expected to have a 5-year DFS of 50%. 
The study was powered to detect an absolute increase of 10% in 
DFS at 5 years, which corresponded to a 26% reduction in the 
risk of relapse and was considered to be a clinically meaningful 
difference. In December 2000, with the approval of the indepen-
dent data monitoring committee and subsequent to approval of 
paclitaxel for lymph node – positive breast cancer by the Food and 
Drug Administration, the study plan was amended so that a 22% 
decrease in the risk of relapse in favor of the experimental 
(docetaxel) treatment was deemed a clinically relevant difference 
and the sample size was increased to 2730. With this amend-
ment, the primary comparison would have a power of 99% to 
detect a clinically relevant difference with a log-rank test at a 
two-sided signiﬁ cance level of .05. The study analysis was to be 
performed by use of a closed testing procedure to ensure that the 
overall type I error remained at the nominal level of .05 ( 13 ). 
The secondary comparisons of sequential docetaxel vs sequential 
control arms and concurrent docetaxel vs concurrent control 
arms would each have a power of 85% to detect a clinically rele-
vant difference. The comparison of docetaxel administered 
sequentially after doxorubicin treatment vs docetaxel adminis-
tered concurrently with doxorubicin treatment would evaluate 
whether the two docetaxel schedules produced equivalent DFS. 
This comparison would be performed by calculating the 95% 
conﬁ dence interval (CI) of the hazard ratio for a DFS event. 
There was 86% probability that this conﬁ dence interval would 
be within the limits of 0.80 to 1.25 if the two docetaxel schedules 
were truly equivalent. 
 The primary efﬁ cacy analysis was the comparison of DFS 
between docetaxel and control treatment groups and was planned 
to be a 5-year analysis, provided that 1215 events had been 
observed. Two interim analyses were planned, at 405 and 810 DFS 
events. The ﬁ rst interim efﬁ cacy analysis was performed after 395 
events, and study continuation was recommended by the indepen-
dent data monitoring committee. By September 2003, it was evi-
dent that the overall event rate in the trial was much lower than 
anticipated; hence, the time to the second interim analysis (810 
events) and main analysis (1215 events) would occur much later 
than planned. After consultation with the independent data moni-
toring committee, an amendment to the study plan was adopted by 
the trial steering committee, in which the main analysis would 
occur after a median follow-up of 5 years or 810 events, whichever 
occurred ﬁ rst. The rationale behind the change was that clinically 
relevant information is generally evident with 5 years of follow-up 
in lymph node – positive breast cancer trials. The change was not 
initiated by the trial sponsor, sanoﬁ -aventis. The main analysis 
would use a two-sided statistical signiﬁ cance level of .0496 to 
account for the interim analysis that had already taken place. 
Future descriptive analyses were planned for 8 years (1215 events) 
and 10 years of follow-up. 
 Trial Sponsors and Funding 
 This trial was sponsored and funded by sanofi-aventis and con-
ducted with BIG: the coordinating group was the Breast European 
Adjuvant Studies Team with the collaboration of eight BIG coop-
erative groups. In some countries, data monitoring was performed 
by sanofi-aventis or their agents. Statistical analyses were per-
formed by the International Drug Development Institute (IDDI) 
statistical center and were done entirely independently from sanofi-
aventis, under the auspices of the BIG. 
 Results 
 Patients 
 From June 10, 1998, through June 26, 2001, 2887 patients with 
lymph node – positive breast cancer were randomly assigned to one 
of the four treatment arms. Baseline characteristics of enrolled 
patients were well balanced ( Table 1 ). The median age of patients 
entered was 49 years (range = 21 – 70 years), and only 4% were older 
than 65 years. Fifty-five percent of patients had undergone a mas-
tectomy, and the remainder had had breast-conserving surgery. 
Patients had a median of three positive lymph nodes among a 
median of 16 axillary lymph nodes resected, and almost half (46% 
of the patients) had four or more positive lymph nodes. The breast 
cancer was hormone receptor – positive in 76% of patients. HER2 
testing of early breast cancer was not routinely performed at par-
ticipating sites during the period of accrual. Twenty-two of the 
2887 randomly assigned patients (1.2% assigned to control and 
0.5% assigned to docetaxel treatment) never commenced their 
allocated protocol treatment (Fig. 2). Results are reported according 
to an intent-to-treat analysis. 
 The mean relative dose intensity received for doxorubicin was 
similar for patients in all treatment arms (96% – 97%). The mean 
relative docetaxel dose intensity received was 95% in the sequen-
tial arm and 97% in the concurrent arm. The mean relative CMF 
dose intensity received was 92% for patients in all treatment 
arms. Granulocyte colony-stimulating factor was administered to 
15% of patients in the sequential control arm, 12% in concur-
rent control arm, 22% in sequential docetaxel arm, and 29% in 
concurrent docetaxel arm. Granulocyte colony-stimulating 
factor was administered during 6% of cycles in the sequential 
control arm, 5% in the concurrent control arm, 7% in the 
sequential docetaxel arm, and 12% in the concurrent docetaxel 
arm. Dose reductions occurred in 18% of patients in the 
sequential control arm, 17% in the concurrent control arm, 
25% in the sequential docetaxel arm, and 20% in the concur-
rent docetaxel arm. In the two control arms, 93% and 94% of 
patients completed all seven chemotherapy cycles. For patients 
randomly assigned to the experimental (docetaxel) treatment 
regimens, 91% completed all nine chemotherapy cycles in 
sequential docetaxel arm and 94% completed all seven chemo-
therapy cycles in the concurrent docetaxel arm. Adjuvant hor-
monal therapy was given to 71% of patients in the sequential 
control arm, 74% in the concurrent control arm, 74% in the 
sequential docetaxel arm, and 75% in the concurrent docetaxel 
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arm. Radiation therapy was administered to 81% of patients, 
who were equally distributed across all treatment arms. 
 Efficacy 
 This analysis was performed on March 10, 2006. The median 
follow-up was 62.5 months (maximum 89 months), and 732 DFS 
events (including relapse [local, regional, or distant]; diagnosis of 
a second primary cancer, including contralateral invasive breast 
cancer; or death from any cause) had occurred ( Table 2 ). Thus, 
after 5 years of follow-up, less than two-thirds of the 1215 events 
originally planned had occurred. Overall, 2.8% of patients were 
lost to follow-up, with equal percentages from control and 
 Table 1 .  Patient characteristics by treatment arm * 
 Characteristic
Sequential 
control arm 
(A → CMF) † 
Concurrent 
control arm 
(AC → CMF) ‡ 
Sequential 
docetaxel arm 
(A → T → CMF) § 
Concurrent 
docetaxel arm 
(AT → CMF) || Total cohort 
 Patients, No. 481 487 960 959 2887 
 Age, % 
  <50 y 53 54 53 53 53 
  ≥ 50 y 47 46 47 47 47 
 No. of positive lymph nodes, % 
  1 – 3 lymph nodes 54 55 54 54 54 
  ≥ 4 lymph nodes 46 45 46 46 46 
 Hormone receptor status, % 
  ER and/or PR positive 75 75 75 77 76 
  ER and PR negative 24 25 24 23 24 
 Menopausal status, % 
  Premenopausal 53 54 53 55 54 
  Postmenopausal 41 40 42 40 41 
  Other ¶ 5 6 6 5 6 
 Tumor stage, % 
  pT1 – 2 94 92 93 91 92 
  pT3 6 7 6 8 7 
 Type of surgery, % 
  Breast conserving 46 45 46 44 55 
  Mastectomy 54 55 54 56 45 
 *  CMF = cyclophosphamide, methotrexate, and 5-fluorouracil; ER = estrogen receptor; PR = progesterone receptor; pT = pathologic tumor stage. Data in various 
categories may not add up to expected values because of rounding. 
 †  Four cycles of doxorubicin followed by CMF (A → CMF). 
 ‡  Four cycles of doxorubicin plus cyclophosphamide followed by CMF (AC → CMF). 
 §  Three cycles of doxorubicin followed by three cycles of docetaxel followed by CMF (A → T → CMF). 
 ||  Four cycles of doxorubicin plus docetaxel followed by CMF (AT → CMF). 
 ¶  Menopausal status was uncertain (eg, previous hysterectomy without oophorectomy). 
 Fig . 2 .  CONSORT diagram for patients in 
Breast International Group (BIG) 02-98 trial. 
Numbers of patients at each stage are shown 
in the  boxes . seq = sequential; con = concur-
rent; A = doxorubicin; CMF = cyclophospha-
mide, methotrexate, and 5-ﬂ uorouracil; C = 
cyclophosphamide; T = docetaxel. 
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docetaxel treatment groups. The most common non-breast sec-
ond primary malignancies were melanoma and colorectal and 
endometrial cancers. There were five cases of leukemia or 
myelodysplasia, with an incidence of 0.3% among patients 
receiving control treatment and 0.1% among patients receiving 
docetaxel. 
 Results of the primary and secondary comparisons are detailed 
in  Table 3 and  Fig. 3 . The primary comparison evaluated the 
incorporation of docetaxel, regardless of its schedule of adminis-
tration, into anthracycline-based crossover adjuvant chemother-
apy. Overall, the addition of docetaxel resulted in improved DFS 
of borderline statistical signiﬁ cance (HR of a DFS event = 0.86, 
95% CI = 0.74 to 1.00;  P = .05). Secondary comparisons, how-
ever, found differences in efﬁ cacy that may have been associated 
with the schedule of administration of adjuvant docetaxel and 
doxorubicin. DFS was better in the sequential docetaxel arm 
(doxorubicin followed by docetaxel followed by CMF) than in the 
sequential control arm (doxorubicin followed by CMF) (HR of a 
DFS event = 0.79, 95% CI = 0.64 to 0.98;  P = .035). DFS was 
similar in the concurrent docetaxel arm (doxorubicin plus 
docetaxel followed by CMF) and the concurrent control arm 
(doxorubicin plus cyclophosphamide followed by CMF) (HR of a 
DFS event = 0.93, 95% CI = 0.75 to 1.14;  P = .48). When the two 
docetaxel arms were compared (doxorubicin followed by docetaxel 
followed by CMF vs doxorubicin plus docetaxel followed by 
CMF), DFS was better in the sequential docetaxel arm than in 
the concurrent docetaxel arm (HR of a DFS event = 0.83, 95% 
CI = 0.69 to 1.00). 
 Five-year DFS was estimated by use of Kaplan-Meier analyses 
for the four treatment arms for all patients and for subgroups 
 Table 3 .  Hazard ratios for disease-free survival in the Breast International Group 02 – 98 Randomized Trial * 
 Comparison
No. of 
patients 
per group
Total 
No. of 
patients
Treatment 
comparison HR (95% CI) †  P value ‡ 
 Primary comparison 
  Docetaxel vs control 1919 vs 968 2887 A → T → CMF + AT → CMF vs 
A → CMF + AC → CMF
0.86 § (0.74 to 1.00) .051 
 Secondary comparisons 
  Sequential docetaxel vs sequential control 960 vs 481 1441 A → T → CMF vs A → CMF 0.79 || (0.64 to 0.98) .035 
  Concurrent docetaxel vs concurrent control 959 vs 487 1446 AT → CMF vs AC → CMF 0.93 (0.75 to 1.14) .48 
  Sequential docetaxel vs concurrent docetaxel 960 vs 959 1919 A → T → CMF vs AT → CMF 0.83 (0.69 to 1.00) Not planned ¶ 
 Hypothesized HR# 0.78  
 *  HR = hazard ratio of an event including local, regional, or distant relapse; diagnosis of a second primary cancer, including contralateral invasive breast cancer; or 
death from any cause; CI = confidence interval; CMF = cyclophosphamide, methotrexate, and 5-fluorouracil; A → T → CMF = doxorubicin followed by docetaxel 
followed by CMF; AT → CMF = doxorubicin + docetaxel followed by CMF; A → CMF = doxorubicin followed by CMF; AC → CMF = doxorubicin + cyclophosphamide 
followed by CMF. 
 †  The primary comparison was stratified for number of positive lymph nodes, age at random assignment to treatment, and schedule of drug administration. 
 ‡  Stratified log rank test. All statistical tests were two-sided. 
 §  For the primary comparison: in the hormone receptor – positive subgroup, HR = 0.86 (95% CI = 0.71 to 1.03); in the hormone receptor-negative subgroup, 
HR = 0.89 (95% CI = 0.69 to 1.15). 
 ||  For the secondary sequential comparison: in the hormone receptor – positive subgroup, HR = 0.79 (95% CI = 0.61 to 1.05); in the hormone receptor-negative 
subgroup, HR = 0.80 (95% CI = 0.55 to 1.15). In the subgroup with one to three positive lymph nodes, HR = 0.85 (95% CI = 0.58 to 1.23); in the subgroup with 
four or more positive lymph nodes, HR = 0.76 (95% CI = 0.58 to 1.00). 
 ¶  This comparison evaluated whether both treatment groups were equivalent, by use of the two-sided 95% confidence intervals only. 
 #  For the primary comparison, a 22% decrease in the risk of a disease-free survival event in favor of docetaxel would represent a clinically relevant difference. 
 Table 2 .  Patients with first events 
 Event
Sequential 
control arm 
(A → CMF) * 
(n = 481)
Concurrent 
control arm 
(AC → CMF) † 
(n = 487)
Sequential 
docetaxel arm 
(A → T → CMF) ‡ 
(n = 960)
Concurrent 
docetaxel arm 
(AT → CMF) § 
(n = 959)
Total cohort 
(n = 2887) 
 Breast cancer relapse, % (No.) 21.8 (105) 24.8 (121) 19.9 (191) 23.5 (225) 22.2 (642) 
 Death, % (No.) 1.5 (7) 0.8 (4) 0.3 (3) 0.6 (6) 0.7 (20) 
 Contralateral breast cancer, % (No.) 1.5 (7) 0.8 (4) 0.2 (2) 0.7 (7) 0.7 (20) 
 Other second primary cancer, % (No.) 2.1 (10) 1.6 (8) 1.9 (18) 1.5 (14) 1.7 (50) 
 Total events || , % (No.) 26.8 (129) 28.1 (137) 22.3 (214) 26.3 (252) 25.4 (732) 
 None || (event-free patients), % (No.) 73.2 (352) 71.9 (350) 77.7 (746) 73.7 (707) 74.6 (2155) 
 *  Four cycles of doxorubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (A → CMF). Data in some categories may not add up to the 
expected amounts because of rounding. 
 †  Four cycles of doxorubicin plus cyclophosphamide followed by CMF (AC → CMF). 
 ‡  Three cycles of doxorubicin followed by three cycles of docetaxel followed by CMF (A → T → CMF). 
 §  Four cycles of doxorubicin plus docetaxel followed by CMF (AT → CMF). 
 ||  The total percentage (numbers) of patients with or without events is shown. 
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according to hormone receptor status, lymph node status, and age 
( Table 4 ). Control patients overall had a 5-year DFS of 73% (95% 
CI = 70% to 75%). For patients in the sequential docetaxel arm, 
the estimated 4-year DFS was 82% (95% CI = 79% to 84%) and 
5-year DFS was 78% (95% CI = 75% to 81%). Fewer than 15% 
of patients with one to three involved lymph nodes who were 
treated in the sequential docetaxel arm had relapsed at 5 years. 
Subgroup analyses did not show any evidence of heterogeneity of 
effect with regard to the efﬁ cacy of docetaxel in subgroups accord-
ing to age, lymph node status, or hormone receptor status. Patients 
with four or more positive lymph nodes and patients with hormone 
receptor – negative disease showed the largest absolute improve-
ment in 5-year DFS when the sequential docetaxel arm (doxorubi-
cin, followed by docetaxel, followed by CMF) was compared with 
the control arms. Patients with hormone receptor – negative tumors 
treated with the sequential docetaxel regimen had a 7% or more 
absolute increase in 5-year DFS compared with either control arm 
or the concurrent docetaxel arm ( Table 4 ). 
 At the time of this analysis, 403 of the 2887 patients had died. 
No statistically signiﬁ cant differences in overall survival were 
observed between patients randomly assigned to docetaxel treat-
ment and those assigned to control treatment (HR of death = 0.92, 
 Fig. 3 .  Disease-free survival (DFS).  A ) Kaplan-
Meier analyses of DFS in docetaxel-treated 
and control patients. Among the 2887 ran-
domly assigned patients included in the 
intention-to-treat analysis, the hazard ratio 
of an event, stratiﬁ ed for lymph node status 
and age, was 0.86 (95% conﬁ dence interval 
[CI] = 0.74 to 1.00;  P = .051). Events, deﬁ ned 
as relapse (local, regional, or distant), diag-
nosis of a second primary cancer includ-
ing contralateral invasive breast cancer, or 
death from any cause, occurred in 466 
patients (24%) in the docetaxel-treated 
patients and 266 patients (27%) in the con-
trol patients. The estimated 5-year DFS for 
all docetaxel-treated patients was 76% (95% 
CI = 74% to 78%) and the estimated 5-year 
DFS for control patients was 73% (95% CI = 
70% to 76%).  B ) Kaplan-Meier analyses for 
DFS by treatment arm. Among the 1441 
patients analyzed in the secondary compari-
son of the sequential docetaxel arm vs the 
sequential control arm, the hazard ratio of 
an event was 0.79 (95% CI = 0.64 to 0.98; 
 P = .035). CMF = cyclophosphamide, metho-
trexate, and 5-ﬂ uorouracil; A → CMF = doxo-
rubicin followed by CMF; AC → CMF = 
doxorubicin plus cyclophosphamide fol-
lowed by CMF; A → T → CMF = doxorubicin 
followed by docetaxel followed by CMF; 
AT → CMF = doxorubicin plus docetaxel fol-
lowed by CMF. 
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95% CI = 0.75 to 1.13). The estimated 5-year overall survival for 
patients randomly assigned to docetaxel treatment was 87% (95% 
CI = 85% to 88%). When survival for patients in the sequential 
docetaxel arm was compared with that of patients in the concur-
rent docetaxel arm, the hazard ratio for death was 0.80 (95% CI = 
0.62 to 1.02). However, given the relatively small number of deaths 
that have occurred within 5 years, overall survival could not be 
adequately assessed at this analysis, and additional follow-up will 
be required to ascertain whether statistically signiﬁ cant differences 
in survival will emerge. 
 Toxicity 
 The percentages of patients who experienced grade 3 or greater 
toxic effects are presented in  Table 5 . Febrile neutropenia was more 
common among docetaxel-treated patients, occurring in 8% of 
patients in the sequential docetaxel arm compared with 12% of 
patients in the concurrent docetaxel arm. Severe anemia and 
thrombocytopenia were infrequent. Blood and platelet transfusion 
were given to 1% and 0.2% of patients, respectively, with similar 
transfusion requirements in control and docetaxel-treated patients. 
Erythropoetin was administered to 0.8% of patients. Hospitalization 
due to an adverse event at any time during treatment or follow-up 
was more frequent among docetaxel-treated patients than control 
patients. Treatment in the sequential docetaxel arm was 6 weeks 
(ie, two cycles) longer than that in the other arms, and more 
patients in the sequential docetaxel arm than in other arms experi-
enced at least one grade 3 – 4 or severe adverse event. Among the 
2865 patients who commenced protocol treatment, four died as the 
result of a toxic event, with an incidence of 0.10% among control 
patients and 0.16% among docetaxel-treated patients. One patient 
in the sequential control arm died of pneumonia during CMF treat-
ment, one in the sequential docetaxel arm died of neutropenic sep-
sis during CMF treatment, one in the concurrent docetaxel arm 
died of probable sepsis during doxorubicin plus docetaxel treat-
ment, and one in the concurrent docetaxel arm died of sepsis with 
cryptococcal meningitis during doxorubicin plus docetaxel treat-
ment. Among these four deaths, two occurred in women aged 60 
years or older, including one with a body weight of 117 kg and a 
body surface area of 2.2 m 2 . The protocol was subsequently 
amended to limit the body surface area to 2.0 m 2 . Two of the four 
deaths occurred during CMF, one in a 65-year-old woman and the 
other in a patient for whom cyclophosphamide had been changed 
to an intravenous route on days 1 and 8 because the oral regimen 
was poorly tolerated. 
 Severe allergic reactions occurred occasionally in docetaxel-
treated patients. Severe asthenia, myalgias, diarrhea, and skin tox-
icity were more frequent in docetaxel-treated patients than in 
control patients. Severe stomatitis was most frequent in the 
patients in the sequential docetaxel arm. Although severe edema 
was rare, edema of all grades was more common in docetaxel-
treated patients (28% of patients) than in control patients (11%). 
Severe neurosensory toxicity was rare, although grade 1 – 2 neuro-
sensory toxicity was frequent among docetaxel-treated patients and 
was more frequently reported among patients receiving sequential 
(47%) than concurrent (24%) docetaxel. Grade 3 – 4 cardiac func-
tion toxicity was observed in 0.5% of control patients and 0% of 
docetaxel-treated patients. Among women who were premeno-
pausal at study entry, amenorrhea was reported in 58% of those in 
the sequential control arm, 63% of those in the concurrent control 
arm, 69% of those in the sequential docetaxel arm, and 61% of 
those in the concurrent docetaxel arm. 
 Discussion 
 The BIG 02-98 trial found a borderline improvement in DFS 
among patients with lymph node – positive breast cancer when 
docetaxel was incorporated into anthracycline-based adjuvant che-
motherapy. The strength of the BIG 02-98 trial is that it is a large 
randomized trial with robust control treatment arms of 24 weeks (6 
months) duration. In a relatively high-risk lymph node – positive 
patient cohort, the control treatments resulted in a 5-year DFS of 
73%. The BIG 02-98 trial, to our knowledge, is the first adjuvant 
trial to report outcomes for sequential vs concurrent anthracycline-
docetaxel therapy. Patients in each docetaxel arm received the same 
cumulative dose of docetaxel. Important differences in outcome 
may be related to doxorubicin and docetaxel scheduling. Sequential 
 Table 4 .  Kaplan-Meier estimates of 5-year disease-free survival in the Breast International Group 02 – 98 Randomized Trial * 
 Group
5-y DFS, % (95% CI) 
 Sequential control 
arm (A → CMF) 
(n = 481)
Concurrent control 
arm (AC → CMF) 
(n = 487)
Sequential docetaxel 
arm (A → T → CMF) 
(n = 960)
Concurrent docetaxel 
arm (AT → CMF) 
(n = 959)
Total cohort 
(n = 2887) 
 All patients 73 (69 to 77) 72 (68 to 76) 78 (75 to 81) 74 (71 to 77) 75 (73 to 76) 
 Hormone receptor status 
  Positive 77 (72 to 81) 77 (72 to 81) 81 (78 to 84) 78 (75 to 81) 79 (77 to 80) 
  Negative 61 (51 to 69) 59 (49 to 67) 68 (62 to 74) 61 (54 to 67) 63 (59 to 66) 
 Lymph node status 
  1 – 3 lymph nodes 84 (78 to 88) 80 (74 to 84) 85 (82 to 88) 81 (77 to 84) 83 (81 to 85) 
  ≥ 4 lymph nodes 61 (54 to 67) 64 (57 to 70) 69 (64 to 73) 66 (61 to 70) 66 (63 to 68) 
 Age, y 
  <50 74 (68 to 79) 73 (67 to 78) 79 (75 to 82) 73 (69 to 77) 75 (73 to 77) 
  ≥ 50 72 (65 to 77) 71 (64 to 77) 77 (72 to 81) 75 (70 to 79) 74 (72 to 77) 
 *  DFS = disease-free survival; CI = confidence interval; CMF = cyclophosphamide, methotrexate, and 5-fluorouracil; A → CMF = doxorubicin followed by CMF; 
AC → CMF = doxorubicin + cyclophosphamide followed by CMF; A → T → CMF = doxorubicin followed by docetaxel followed by CMF; AT → CMF = doxorubicin + 
docetaxel followed by CMF. 
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administration of docetaxel after doxorubicin appeared to produce 
better DFS than anthracycline-based adjuvant chemotherapy, but 
concurrent administration of these agents did not. 
 Two randomized trials have recently reported that adjuvant 
treatment with docetaxel improves survival of patients with lymph 
node – positive breast cancer. In the Breast Cancer International 
Research Group (BCIRG) 001 trial ( 14 ) ( Table 6 ), patients with 
lymph node – positive breast cancer were randomly assigned to 
adjuvant chemotherapy with six cycles of docetaxel (75 mg/m 2 ), 
doxorubicin (50 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ) or of 
5-ﬂ uorouracil (500 mg/m 2 ), doxorubicin (50 mg/m 2 ), and cyclo-
phosphamide (500 mg/m 2 ). The trial showed a statistically signiﬁ -
cant improvement in DFS and overall survival for patients receiving 
docetaxel. The French Protocol Adjuvant dans le Cancer du Sein 
(PACS) 01 trial ( 15 ) ( Table 6 ) randomly assigned patients to six 
cycles of 5-ﬂ uorouracil, epirubicin (100 mg/m 2 ), and cyclophos-
phamide (ie, FEC100) or to three cycles of FEC100 followed by 
three cycles of docetaxel at 100 mg/m 2 . Patients in the sequential 
docetaxel arm had statistically signiﬁ cantly better DFS and overall 
survival than those receiving six cycles of FEC100. In the BIG 02-
98 trial, the results for 5-year DFS in the sequential docetaxel and 
sequential control arms were identical to those in the PACS 01 
trial, at 78% and 73%, respectively  ( Table 6 ). The results of the 
BIG 02-98 trial are consistent with those of the reported adjuvant 
docetaxel trials ( 14 , 15 ). Although the BCIRG 001 trial showed a 
somewhat greater reduction in the relative risk of relapse than the 
PACS 01 and BIG 02-98 trials, patients in the control arm of the 
BCIRG 001 trial received a lower dose intensity of anthracycline 
than patients in the control arms of the other two trials. Among all 
published adjuvant taxane trials, the crossover anthracycline-CMF 
strategy used in the BIG 02-98 trial was the only control treatment 
that has been shown to be superior to classic CMF ( 16 ). 
 The higher DFS observed in the sequential docetaxel arm 
than in the concurrent docetaxel arm in the BIG 02-98 trial may 
have several possible explanations. Although both arms had the 
same cumulative dose of docetaxel, the dose per cycle of both 
doxorubicin and docetaxel were higher in the sequential docetaxel 
arm than in the concurrent docetaxel arm. The higher dose of 
docetaxel in the sequential docetaxel arm (100 mg/m 2 ) may be 
superior to the lower dose in the concurrent docetaxel arm 
(75 mg/m 2 ). In advanced breast cancer patients, a phase III trial 
evaluating different doses of docetaxel found evidence of a dose-
response relationship ( 17 ). In the BIG 02-98 trial, the cumula-
tive dose of doxorubicin (225 mg/m 2 ) in the sequential docetaxel 
arm was higher than that in the concurrent docetaxel arm (200 
mg/m 2 ). The sequential docetaxel treatment was also 6 weeks 
(two cycles) longer than the other treatment arms, which were 
each 24 weeks long. 
 Three decades ago, Norton and Simon ( 18 ) reported that the 
growth of solid neoplasms could be described by Gompertzian 
 Table 5 .  Patients experiencing grade 3 or higher toxicity * 
 Toxic effect
Sequential control 
arm † , % of patients
Concurrent control 
arm ‡ , % of patients
Sequential docetaxel 
arm § , % of patients
Concurrent docetaxel 
arm || , % of patients 
 Febrile neutropenia (protocol 
 defined ¶ ) # 
5 4 8 12 ** 
 Febrile neutropenia † † 8 5 12 16 
 Infection # 5 4 6 7 
 Anemia 3 2 3 3 
 Thrombocytopenia 3 2 2 2 
 Allergy 0.0 0.0 1.7 0.9 
 Asthenia # 4 4 7 6 
 Cardiac function 0.4 0.6 0.0 0.0 
 Edema 0.0 0.0 0.1 0.2 
 Diarrhea # 0 2 3 3 
 Myalgia # 0.4 0.0 3.1 ‡ ‡ 0.8 
 Neurosensory 0.0 0.0 0.6 0.2 
 Skin # 0.8 0.6 3.3 ‡ ‡ 0.3 
 Stomatitis # 5 2 7 ‡ ‡ 4 
 At least one treatment-related 
 grade 3 or 4 or severe AE # 
20 23 32 ‡ ‡ 25 
 Hospitalization due to AE # 17 12 20 20 
 Toxic deaths 0.2 0 0.1 0.2 
  *  AE = adverse event; CMF = cyclophosphamide, methotrexate, and 5-fluorouracil. 
  †  Four cycles of doxorubicin followed by CMF. 
  ‡  Four cycles of doxorubicin plus cyclophosphamide followed by CMF. 
  §  Three cycles of doxorubicin followed by three cycles of docetaxel followed by CMF. 
  ||  Four cycles of doxorubicin plus docetaxel followed by CMF. 
  ¶  Protocol-defined febrile neutropenia was grade 4 neutropenia, fever higher than 38°C with either hospitalization or antibiotics. 
  #  Statistically significantly higher in docetaxel-treated patients than control patients. 
 **   Statistically significantly higher ( P = .002) in the concurrent docetaxel arm than in the sequential docetaxel arm. 
 † †   Grade 3 or 4 neutropenia and fever higher than 38°C. 
 ‡ ‡  Statistically significantly higher in the sequential docetaxel arm than in the concurrent docetaxel arm. 
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curves, in which the rate of regrowth of a tumor increases as the 
tumor shrinks in response to therapy. The Norton – Simon 
hypothesis ( 19 ) predicted that this resistance might be overcome 
by switching from initial chemotherapy agents to new agents at 
the maximally tolerated dose. In the BIG 02-98 trial, the better 
results observed in the sequential docetaxel arm than in the con-
current docetaxel arm are consistent with this hypothesis; how-
ever, design issues (ie, dose, schedule, or treatment duration) 
preclude deﬁ nitive conclusions as to which factors are most 
important. Results of other adjuvant trials, such as BCIRG 005 
and NSABP B-30 trials, that are testing sequential and concur-
rent anthracycline-docetaxel regimens, have not yet been 
reported. 
 Previous studies by the German Breast Group in the neoad-
juvant setting ( 20 ) and by Grupo Español de Investigacion en 
Cancer de Mama in metastatic disease ( 21 ) showed higher com-
plete response rates with sequential anthracycline–docetaxel 
scheduling than with concurrent scheduling and thus are consis-
tent with our results. Sequential anthracycline–docetaxel–CMF 
adjuvant chemotherapy treatment provides exposure to drugs 
that may be effective in eradicating occult micrometastases, 
even if tumor cells are resistant to some of the drugs adminis-
tered. Trials in anthracycline-resistant advanced breast cancer 
show that approximately half of patients with such disease will 
respond to docetaxel ( 7 , 8 ). Crossover treatment to CMF can 
increase the likelihood of a complete response after doxorubi-
cin. In a trial conducted in patients with measurable metastatic 
breast cancer, patients initially received four cycles of single-
agent doxorubicin (75 mg/m 2 ) followed by a crossover to four 
cycles of CMF. Among 41 evaluable patients who were pre-
dominantly treatment naive, the complete response rate was 
17% after doxorubicin, and it increased to 30% after comple-
tion of CMF ( 22 ). 
 In the BIG 02-98 trial, women in the concurrent docetaxel 
arm (doxorubicin plus docetaxel followed by CMF) showed no 
statistically signiﬁ cant improvement in outcome compared with 
women in the concurrent control arm (doxorubicin plus cyclo-
phosphamide followed by CMF). This result may reﬂ ect the fact 
that a reduction in the dose of each drug is required to safely 
administer doxorubicin and docetaxel concurrently. Other trials 
have also reported similar results from concurrent administra-
tion of doxorubicin and docetaxel compared with concurrent 
doxorubicin and cyclophosphamide; these trials include a phase 
III preoperative trial conducted by the Anglo-Celtic Group ( 23 ) 
and a phase III adjuvant trial conducted by the Eastern 
Cooperative Oncology Group among patients with zero to three 
involved axillary lymph nodes ( 24 ). The Eastern Cooperative 
Oncology Group trial compared four cycles of doxorubicin 
(60 mg/m 2 ) combined with docetaxel (60 mg/m 2 ) with four cycles 
of doxorubicin (60 mg/m 2 ) plus cyclophosphamide (600 mg/m 2 ), 
and it is plausible that the reduced dose of docetaxel in the com-
bination treatment in this trial may have compromised its efﬁ -
cacy ( Table 6 ). Interestingly, a randomized trial of adjuvant 
therapy conducted by US Oncology among patients with pre-
dominantly zero to three positive lymph nodes reported improved 
DFS when docetaxel (75 mg/m 2 ) was substituted for doxorubicin 
(60 mg/m 2 ) in combination with cyclophosphamide (600 mg/m 2 ). 
In that trial, the 5-year DFS for four cycles of docetaxel plus 
cyclophosphamide was 86% compared with 80% for doxorubi-
cin plus cyclophosphamide (HR = 0.67, 95% CI = 0.50 to 0.94; 
 P = .015) ( 25 ). 
 In the BIG 02-98 trial, acute toxic effects, including severe 
adverse events and hospitalization, were more frequent for 
patients randomly assigned to docetaxel arms than to control 
arms. Although treatment-related mortality was low, 20% of 
patients in the docetaxel treatment group were hospitalized 
because of an adverse event. One-third of women treated with 
the sequential docetaxel regimen experienced at least one treat-
ment-related severe adverse event, although many women with 
early breast cancer will accept acute toxic effects for a small 
chance of improved survival ( 26 , 27 ). However, late or persistent 
toxic effects are becoming more important because an increasing 
proportion of patients remain disease free after treatment for 
early breast cancer. The docetaxel arms in the BIG 02-98 trial 
 Table 6 .  Adjuvant breast cancer trials testing the efficacy of docetaxel * 
 Trial
Lymph node status, 
% of patients Docetaxel arm Control arm
HR (95% CI)  0 LN 1 – 3 LN  ≥ 4 LN Regimen DFS † , % Regimen DFS, % 
 ECOG 2197 65 35 0 AT × 4 87 AC × 4 87 1.08 (0.89 to 1.31) 
 US Oncology 47 41 12 TC × 4 86 AC × 4 80 0.67 (0.50 to 0.94) 
 BCIRG 001 0 62 38 TAC × 6 75 FAC × 6 68 0.72 (0.59 to 0.88) 
 PACS 01 0 62 38 FEC × 3 → T × 3 78 FEC × 6 73 0.82 (0.69 to 0.99) 
 BIG 02-98  
  Sequential arms 0 54 46 A × 3 → T × 3 → CMF × 3 78 A × 4 → CMF × 3 73 0.79 (0.64 to 0.98) 
  Concurrent arms 0 54 46 AT × 4 → CMF × 3 74 AC × 4 → CMF × 3 72 0.93 (0.75 to 1.14) 
 *  DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; LN = positive lymph node(s); ECOG = Eastern Cooperative Oncology Group; AT × 4 = 
four cycles of doxorubicin + docetaxel; AC × 4 = four cycles of doxorubicin + cyclophosphamide; TC × 4 = four cycles of docetaxel + cyclophosphamide; 
BCIRG = Breast Cancer International Research Group; TAC × 6 = six cycles of docetaxel + doxorubicin + cyclophosphamide; FAC × 6 = six cycles of 5-fluorouracil + 
doxorubicin + cyclophosphamide; PACS = Protocol Adjuvant dans le Cancer du Sein; FEC × 3 → T × 3 = three cycles of 5-fluorouracil + epirubicin + cyclophospha-
mide followed by three cycles of docetaxel; FEC × 6 = six cycles of 5-fluorouracil + epirubicin + cyclophosphamide; BIG = Breast International Group; 
CMF = cyclophosphamide, methotrexate, and 5-fluorouracil; A × 3 → T × 3 → CMF × 3 = three cycles of doxorubicin followed by three cycles of docetaxel fol-
lowed by three cycles of CMF; A × 4 → CMF × 3 = four cycles of doxorubicin followed by three cycles of CMF; AT × 4 → CMF × 3 = four cycles of doxorubicin + 
docetaxel followed by three cycles of CMF; AC × 4 → CMF × 3 = four cycles of doxorubicin + cyclophosphamide followed by three cycles of CMF. 
 †  DFS reported is 5-year DFS for the listed trials with the exception of ECOG 2197 trial for which 4-year DFS is reported. 
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had the advantage of limiting the cumulative dose of doxorubicin, 
whereas the more effective adjuvant regimens without taxanes 
have relatively high cumulative doses of anthracyline, which 
increases the risks for cardiac toxic effects and leukemia. In the 
BIG 02-98 trial, overall 0.8% of patients in control arms experi-
enced grade 3 – 4 cardiac functional toxic effects, leukemia, or 
myelodysplasia compared with 0.1% of patients in the docetaxel 
treatment arms. Neurotoxicity may persist after therapy, particu-
larly if it is severe. Grade 3 neurosensory toxicity was rare (<1%) 
among docetaxel-treated patients in the BIG 02-98 trial, which 
appears to be less frequent than reported with patients receiving 
dose-dense paclitaxel (4%) in the Cancer and Leukemia Group B 
trial 9741 and with patients in the weekly paclitaxel arm (8%) in 
the Intergroup E1199 trial ( 28 , 29 ). Although sequential docetaxel 
treatment in the BIG 02-98 trial was a relatively prolonged regi-
men compared with the docetaxel, doxorubicin, and cyclophos-
phamide (TAC) or dose-dense paclitaxel regimen, it has the 
potential advantages of minimizing the cumulative anthracycline 
dose, a low risk of severe neurotoxicity, and reducing the need 
for growth factors and transfusions compared with the other 
regimens. The estimated 4-year DFS of 82% for the sequential 
docetaxel arm in the BIG 02-98 trial appears similar to the esti-
mated 4-year DFS of 82% reported by Citron et al. ( 28 ) for dose-
dense anthracyline- paclitaxel therapy. 
 The BIG 02-98 trial has potential limitations. The analysis 
was performed after a median follow-up of at least 5 years but 
with less than two-thirds of the number of DFS events origi-
nally planned. Therefore, the study had reduced power to 
address the questions it was designed to answer. The results 
favoring the sequential docetaxel arm may have arisen by 
chance. Survival could not be adequately assessed at the time of 
this analysis. Analysis by HER2 status was not done but, in the 
future, such an analysis may provide additional insights into the 
trial results. 
 Lower-than-anticipated event rates, as observed in the BIG 02-
98 trial, have been observed in some other recent adjuvant breast 
trials ( 24 , 29 ) and indicate how outcomes for patients with lymph 
node – positive breast cancer have improved over time. Among 
women with one to three positive lymph nodes in the BIG 02-98 
trial who were randomly assigned to the sequential docetaxel arm, 
85% were disease free at 5 years. Given that 76% of patients in the 
trial had hormone receptor – positive disease, endocrine therapy 
contributed to the favorable outcome. Patients with endocrine-
responsive disease remain at risk for late events, which will be 
assessed during the protocol-speciﬁ ed 10-year follow-up. 
Translational studies in the BIG 02-98 trial may help to deﬁ ne 
the relationship between pathologic and molecular markers and a 
beneﬁ t from adjuvant docetaxel. 
 Incorporating docetaxel into anthracycline-based adjuvant 
therapy for patients with lymph node – positive breast cancer 
resulted in a borderline improvement in DFS. However, impor-
tant differences may be related to doxorubicin and docetaxel 
scheduling, with sequential, but not concurrent, administration 
appearing to produce better DFS than anthracycline-based adju-
vant chemotherapy. With optimal adjuvant therapy, most patients 
with lymph node – positive breast cancer can now look forward to 
long-term survival. 
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